Capricor Therapeutics (NASDAQ: CAPR) presented five-year data from its HOPE-2 Open-Label Extension study of deramiocel, a cell therapy candidate for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE